Literature DB >> 7094982

The long-term effect of verapamil on plasma digoxin concentration and renal digoxin clearance in healthy subjects.

K E Pedersen, A Dorph-Pedersen, S Hvidt, N A Klitgaard, K K Pedersen.   

Abstract

Single-dose investigations in healthy subjects have demonstrated substantial impairment of renal and extrarenal clearance of digoxin during coadministration of verapamil. A longitudinal study has been performed to assess the changes in digoxin disposition during long-term verapamil therapy. After one week of verapamil 240 mg/d mean plasma digoxin had risen from 0.21 +/- 0.01 ng/ml (SE) to 0.34 +/- 0.01 ng/ml(p less than 0.01), and renal digoxin clearance had fallen from 197.57 +/- 17.37 ml/min to 128.20 +/- 10.33 ml/min (p less than 0.001). These changes gradually subsided, and after six weeks, renal digoxin clearance had normalized and plasma digoxin had declined to 0.27 +/0 0.02 ng/ml (NS). The 24-h urinary recovery of digoxin increased from 46.46 +/- 3.23% before to 69.78 +/- 3.69% (p less than 0.001) after six weeks of verapamil co-administration, and this elevation persisted throughout the study. The verapamil-induced suppression of renal digoxin elimination disappears over a few weeks of drug exposure, whereas the inhibition of the extrarenal clearance of digoxin seems to persist.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7094982     DOI: 10.1007/BF00542456

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  8 in total

1.  Digoxin plasma concentrations and nifedipine.

Authors:  G G Belz; P E Aust; R Munkes
Journal:  Lancet       Date:  1981-04-11       Impact factor: 79.321

2.  Increased clearance of digoxin in rabbits during repeated administration.

Authors:  H R Ochs; G Bodem; G Bales; D J Greenblatt; T W Smith
Journal:  J Pharmacol Exp Ther       Date:  1978-02       Impact factor: 4.030

3.  The effect of quinidine on digoxin kinetics in cardiac patients.

Authors:  K E Pedersen; J Hastrup; S Hvidt
Journal:  Acta Med Scand       Date:  1980

4.  Verapamil-digoxin interaction.

Authors:  H O Klein; R Lang; E Di Segni; E Kaplinsky
Journal:  N Engl J Med       Date:  1980-07-17       Impact factor: 91.245

5.  The acute changes seen in cardiac glycoside receptor sites, 86rubidium uptake and intracellular sodium concentrations in the erythrocytes of patients during the early phases of digoxin therapy are not found during chronic therapy: pharmacological and therapeutic implications for chronic digoxin therapy.

Authors:  A R Ford; J K Aronson; D G Grahame-Smith; J G Carver
Journal:  Br J Clin Pharmacol       Date:  1979-08       Impact factor: 4.335

6.  Digoxin-verapamil interaction.

Authors:  K E Pedersen; A Dorph-Pedersen; S Hvidt; N A Klitgaard; F Nielsen-Kudsk
Journal:  Clin Pharmacol Ther       Date:  1981-09       Impact factor: 6.875

7.  Spironolactone-induced changes in digoxin kinetics.

Authors:  S Waldorff; J D Andersen; N Heebøll-Nielsen; O G Nielsen; E Moltke; U Sørensen; E Steiness
Journal:  Clin Pharmacol Ther       Date:  1978-08       Impact factor: 6.875

8.  Digoxin-quinidine interaction Pharmacokinetic evaluation.

Authors:  W D Hager; P Fenster; M Mayersohn; D Perrier; P Graves; F I Marcus; S Goldman
Journal:  N Engl J Med       Date:  1979-05-31       Impact factor: 91.245

  8 in total
  26 in total

Review 1.  Pharmacokinetic interactions with calcium channel antagonists (Part II).

Authors:  K D Schlanz; S A Myre; M B Bottorff
Journal:  Clin Pharmacokinet       Date:  1991-12       Impact factor: 6.447

Review 2.  Calcium antagonists--adverse drug interactions.

Authors:  H Reicher-Reiss; H N Neufeld; F X Ebner
Journal:  Cardiovasc Drugs Ther       Date:  1987-12       Impact factor: 3.727

Review 3.  Calcium antagonists in patients with heart failure. A review.

Authors:  H Reicher-Reiss; E Barasch
Journal:  Drugs       Date:  1991-09       Impact factor: 9.546

Review 4.  Pharmacokinetic interactions with digoxin.

Authors:  S M Rodin; B F Johnson
Journal:  Clin Pharmacokinet       Date:  1988-10       Impact factor: 6.447

Review 5.  Clinical pharmacokinetics of calcium antagonists. An update.

Authors:  J G Kelly; K O'Malley
Journal:  Clin Pharmacokinet       Date:  1992-06       Impact factor: 6.447

6.  Interaction between Ca2+ antagonists and digitalis.

Authors:  J N Lessem
Journal:  Cardiovasc Drugs Ther       Date:  1988-01       Impact factor: 3.727

7.  Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: II. Ritonavir effects on CYP3A and P-glycoprotein activities.

Authors:  E D Kharasch; P S Bedynek; A Walker; D Whittington; C Hoffer
Journal:  Clin Pharmacol Ther       Date:  2008-10       Impact factor: 6.875

8.  Population Pharmacokinetic Studies of Digoxin in Adult Patients: A Systematic Review.

Authors:  Mariam Abdel Jalil; Noura Abdullah; Mervat Alsous; Khawla Abu-Hammour
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2021-05       Impact factor: 2.441

9.  Verapamil-induced changes in digoxin kinetics in cirrhosis.

Authors:  I Maragno; C Gianotti; P F Tropeano; V Rodighiero; R M Gaion; C Paleari; R Prandoni; L Menozzi
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

10.  Effect of coadministration of verapamil and quinidine on serum digoxin concentration.

Authors:  W Doering
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.